Incannex (ASX: IHL) engages Procaps to encapsulate its anti-inflammatory candidate IHL-675A
2021-07-16 05:52:59 (AET) by Ring Zhang 419
Incannex Healthcare Limited (ASX: IHL), a clinical stage pharmaceutical development company, announced the engagement of Procaps S.A. to develop the specific formulation and soft gel capsules of the company’s CBD-infused anti-inflammatory drug candidate IHL-675A.
Incannex Healthcare Limited (ASX: IHL), a clinical-stage pharmaceutical development company, announced the engagement of Procaps S.A. to develop the specific formulation and soft gel capsules of the company’s CBD-infused anti-inflammatory drug candidate IHL-675A.
Procaps has extensive scientific expertise and has successfully developed over 500 formulations for both pharmaceutical and nutritional products reaching over 50 markets globally.
The manufacture of IHL-675A will take place within its GMP manufacturing processing plants that make drugs certified for prescription by doctors.
IHL-675A is a drug that combines hydroxychloroquine (HCQ) and cannabidiol (CBD). Previous pre-clinical studies, both in vivo and in vitro, conducted by IHL have suggested that IHL-675A is an excellent candidate for prevention and treatment of inflammatory conditions, including lung inflammatory conditions(COPD, asthma, and bronchitis), rheumatoid arthritis and inflammatory bowel disease.
Results from an animal study in March this year demonstrated that IHL-675A has stronger anti-inflammatory properties in the treatment of rheumatoid arthritis than a widely used existing medication called Plaquenil, but with potentially reduced side effects.
Following the guidance from FDA meeting, IHL is now undertaking clinical programs to work towards submitting three new New Drug Applications for IHL-675A for lung inflammation, inflammatory bowel disease and rheumatoid arthritis, to unlock the potential of the drug candidate to become a multi-use medicine.
About Incannex Healthcare Limited (ASX: IHL)
Incannex Healthcare Limited (ASX: IHL) is a first-in-class innovator and developer of a diversified mix of medicinal cannabis pharmaceutical products for global export potential and long-term value creation.
Incannex is currently undertaking clinical programs to develop 4 uniquely formulated medicinal cannabis products for the treatment of Obstructive Sleep Apnoea (OSA_IHL-42X), Traumatic Brain Injury/Concussion (TBI_IHL-216A), Temporomandibular Joint Disorder (TMJD_IHL-493C), and sepsis-associated Adult Respiratory Distress Syndrome (SAARDS_IHL-675A).
Each indication represents major global markets representing total addressable markets of billions of dollars per annum. 3 of the 4 indications currently have no existing registered pharmacotherapy (drug) treatment, raising the possibility of patients receiving Government subsidies for products that demonstrate suitable safety and efficacy profile in clinical trials.
There is an established body of research evidence validating the hypothesis for the cannabinoids being used in Incannex’s chosen therapeutic areas and IHL has a strong patent filing strategy as it develops its products in conjunction with its medical advisory board of global key opinion leaders.
Further to its clinical programs, Incannex also has its Australian licenses in place to import, export and distribute medicinal cannabis products and has launched a line of EU GMP approved CBD oil products under the brand, “INCANNEX”. The INCANNEX cannabis-based oils are sold under Incannex’s product supply and distribution agreement with Cannvalate Pty Ltd, which is the largest network of cannabis medicine prescribers in Australia.
For IHL stock price charting, ASX announcements and mor information, please click IHL stocks page
Source: IHL ASX announcement